Document is current
Any future updates will be listed below
-
Authors
Lindner, Lisa https://orcid.org/0000-0001-8416-0463
Weiß, Anja https://orcid.org/0000-0003-2069-2190
Reich, Andreas https://orcid.org/0000-0002-3729-0772
Baumann, Christine
Behrens, Frank https://orcid.org/0000-0001-8750-7186
Baraliakos, Xenofon https://orcid.org/0000-0002-9475-9362
Regierer, Anne C. https://orcid.org/0000-0003-2456-4049
-
Funding
Funding for this research was provided by:
Deutsches Rheuma-Forschungszentrum Berlin (DRFZ)
- License Information
-
More Information
Article History
Received: 9 July 2025
Accepted: 11 September 2025
First Online: 2 October 2025
Declarations
:
: RABBIT-SpA is approved by the Ethics Committee of Charité University Medicine, Berlin (#EA1/246/16). Participants have to consent to participate in the study.
: Not applicable.
: LL: The author declares that they have no competing interests. AW: The author declares that they have no competing interests. AR: The author declares that they have no competing interests. CB: The author declares that they have no competing interests. FB: grants/research support from Bionorica, Bristol Myers Squibb, Chugai, Iron4u, Janssen-Cilag, LEO Pharma, Novartis, Pfizer, and Roche andmeeting support, honoraria, or fees for serving as a speaker, consultant, and/or advisory board member from AbbVie, Affibody, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Galapagos, GSK, Janssen-Cilag, MoonLake, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, Sanofi , and UCB. XB: Consultant, Scientific Advisory Board: Abbvie, Advanz, Alexion, Alphasigma, Amgen, AstraZeneca, BMS, Cesas, Celltrion, Clarivate, Galapagos, J&J, Lilly, Moonlake, Novartis, Peervoice, Pfizer, Roche, Sandoz, Springer, Stada, Takeda, UCB, Zuellig. Research Grants: Abbvie, Celltrion, Janssen, Moonlake, Novartis. Non-commercial disclosures: ASAS Past President, EULAR President-Elect. ACR: Speaker fees from Amgen, BMS, Novartis.
